Resonant Clinical Solutions renforce ses capacités de thérapies de pointe et de stockage cryogénique grâce à l'acquisition de Creapharm Bioservices

Resonant Clinical Solutions has announced the acquisition of Creapharm Bioservices, a specialized biobanking service provider based in Bailly-Romainvilliers, France. The deal, which was finalized on September 6, 2026, involves an undisclosed amount and aims to enhance Resonant's biobanking capabilities in Europe, particularly in support of complex clinical programs focused on cell and gene therapies. The acquisition underscores Resonant's commitment to expanding its service offerings within the life sciences sector.

Creapharm Bioservices specializes in cryogenic storage and biobanking services for biotherapeutics and advanced therapy medicinal products (ATMPs). The company provides critical services such as vapor phase nitrogen storage at -196 °C, mechanical freezer storage, and compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP). This acquisition allows Resonant to strengthen its infrastructure and expertise in handling sensitive biological materials, which is increasingly important as clinical development programs evolve toward more specialized modalities.

The strategic rationale behind the acquisition lies in the growing demand for specialized biobanking services. According to a report by IQVIA published in August 2025, non-small molecules, including advanced modalities, accounted for 46% of clinical trials in phases I to III launched in 2024, up from 38% five years prior. This trend indicates a significant shift in the types of therapies being developed, necessitating advanced storage and handling capabilities that Creapharm offers. By integrating Creapharm into its Biorepository division, Resonant aims to better support clients managing increasingly complex clinical trials.

Resonant Clinical Solutions has positioned itself as a global partner for life sciences companies, providing comprehensive clinical supply chain solutions. With over 850 employees across the United States, the United Kingdom, and Europe, the company has facilitated more than 2,500 clinical trials and managed over 100 million research assets in storage. The addition of Creapharm's specialized services enhances Resonant's existing capabilities in biobanking, kit preparation, and supply chain management, allowing the company to offer a more robust suite of services to its clients.

The acquisition of Creapharm Bioservices reflects broader trends within the life sciences sector, where the complexity of clinical trials is increasing. As companies seek to develop innovative therapies that require specialized handling and storage, the demand for expert partners like Resonant is likely to grow. This transaction positions Resonant favorably in the competitive landscape, enabling it to better meet the needs of its clients and support the advancement of critical clinical programs globally.